GLP-1 Peptide Atlas, by Delfa

CompletedPhase 1Results posted

A Study of LY3502970 in Healthy Overweight and Obese Participants

A Multiple Dose Study in Healthy Overweight and Obese Participants to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3502970

Lead sponsor

Eli Lilly and Company

Asset

Orforglipron

Oral · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Healthy volunteers, Obesity / overweight

Key I/E criterion

—

Primary endpoints

•One or More Treatment Emergent Adverse Events (TEAEs)•Treatment-emergent AEs (any) (Treatment-emergent AEs (any), Serious AEs (any))

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05313802

Org study ID18453

Secondary IDJ2A-MC-GZGKEli Lilly and Company

Timeline

Milestones

Study first posted2022-04-06actual

Study start2022-05-26actual

Primary completion2022-09-09actual

Study completion2022-09-09actual

Last update posted2026-05-26actual

Results first posted2026-05-26actual

Assets

Investigational agents

Orforglipron

Study populations

Who this study enrolls

Healthy volunteersObesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

Maximum age70 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Participants with stable body weight for at least one month prior to randomization.

•Participants with body mass index (BMI) of greater than or equal to (≥) 27.0 kilograms per meter squared (kg/m²)

•Male participants who agree to use highly effective/effective methods of contraception and female participants not of childbearing potential

Exclusion criteria

•Have known allergies to LY3502970 or other glucagon-like peptide-1 Receptor Agonists (GLP-1 RA) analogs

•Significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders

•Have any type of diabetes with hemoglobin A1c (HbA1c) ≥6.5 %

Endpoints (13)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK

Weight & body composition

2 endpoints

Secondary/registry result

Pharmacodynamics (PD): Change From Baseline in Body Weight

Time frame:Baseline through Day 29

change from baseline, improvement

Posted result

Group	Value (mean), kilograms (kg)	95% CI
LY3502970 Cohort 1	-4.2	—
LY3502970 Cohort 2	-5.5	—
LY3502970 Cohort 3	-3.6	—

Secondary/protocol endpoint

Pharmacodynamics (PD): Change From Baseline in Body Weight

Time frame:Predose through Day 28

Body weight, absolute change (kg)

change from baseline, improvement

Safety / tolerability / PK

11 endpoints

Primary/registry result

Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Time frame:Baseline up to Day 42

event count, event

Posted result

Group	Value (number), participants	95% CI
LY3502970 Cohort 1	20	—
LY3502970 Cohort 2	21	—
LY3502970 Cohort 3	16	—

Primary/protocol endpoint

Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Time frame:Predose up to 42 days

Treatment-emergent AEs (any)

event count, event

componentsTreatment-emergent AEs (any), Serious AEs (any)

Secondary/registry result

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970 on Day 1

Time frame:Day 1 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose)

concentration, descriptive

Posted result

Group	Value (geometric_mean), nanogram hour per milliliter (ng*h/mL)	95% CI
LY3502970 Cohort 1	117	—
LY3502970 Cohort 2	66.1	—
LY3502970 Cohort 3	66.9	—

Secondary/registry result

PK: Maximum Observed Concentration (Cmax) of LY3502970 on Day 1

Time frame:Day 1 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose)

concentration, descriptive

Posted result

Group	Value (geometric_mean), nanograms per milliliter (ng/mL)	95% CI
LY3502970 Cohort 1	8.40	—
LY3502970 Cohort 2	4.97	—
LY3502970 Cohort 3	5.00	—

Secondary/registry result

PK: Time to Maximum Observed Concentration (Tmax) of LY3502970 on Day 1

Time frame:Day 1 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose)

time to event, event

Posted result

Group	Value (median), hours (h)	95% CI
LY3502970 Cohort 1	7.03	4.00 – 8.00
LY3502970 Cohort 2	6.00	4.00 – 8.00
LY3502970 Cohort 3	6.00	4.00 – 8.00

Secondary/registry result

PK: AUC[0-tlast] of LY3502970 on Day 28

Time frame:Day 28 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose)

concentration, descriptive

Posted result

Group	Value (geometric_mean), ng*h/mL	95% CI
LY3502970 Cohort 1	275	—
LY3502970 Cohort 2	277	—
LY3502970 Cohort 3	314	—

Secondary/registry result

PK: Cmax of LY3502970 on Day 28

Time frame:Day 28 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose)

concentration, descriptive

Posted result

Group	Value (geometric_mean), ng/mL	95% CI
LY3502970 Cohort 1	18.4	—
LY3502970 Cohort 2	18.4	—
LY3502970 Cohort 3	21.2	—

Secondary/registry result

PK: Tmax of LY3502970 on Day 28

Time frame:Day 28 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose)

concentration, descriptive

Posted result

Group	Value (median), h	95% CI
LY3502970 Cohort 1	6.00	4.00 – 12.00
LY3502970 Cohort 2	6.00	4.00 – 12.00
LY3502970 Cohort 3	6.00	4.00 – 8.00

Secondary/protocol endpoint

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3502970

Time frame:Predose up to 29 days postdose

AUC₀–∞

concentration, descriptive

Secondary/protocol endpoint

PK: Maximum Observed Concentration (Cmax) of LY3502970

Time frame:Predose up to 29 days postdose

Cmax

concentration, descriptive

Secondary/protocol endpoint

PK: Time to Maximum Observed Concentration (Tmax) of LY3502970

Time frame:Predose up to 29 days postdose

Tmax

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.